• 1. An insight into the hybridization mechanism of hairpin DNA physically immobilized on chemically modified graphenes
  Adeline Huiling Loo,Alessandra Bonanni,Martin Pumera Analyst, 2013,138, 467-471
• 2. An integrated process of CO2 capture and in situ hydrogenation to formate using a tunable ethoxyl-functionalized amidine and Rh/bisphosphine system?
  Yu-Nong Li,Liang-Nian He,Xian-Dong Lang,Xiao-Fang Liu,Shuai Zhang RSC Adv., 2014,4, 49995-50002
• 3. An analysis of the WTC fires using CIB correlations and simple modeling
  JGQuintiere
• 4. An atlas of endohedral Sc2S cluster fullerenes?
  Li-Hua Gan,Rui Wu,Jian-Lei Tian,Patrick W. Fowler Phys. Chem. Chem. Phys., 2017,19, 419-425
• 5. An approach to 7-aza-1-phosphanorbornane complexes: strain promoted rearrangement of 1-iminylphosphirane complexes and cycloaddition with olefins?
  Yang Xu,Min Wang,Donghui Wei,Rongqiang Tian,Zheng Duan,Fran?ois Mathey Dalton Trans., 2019,48, 5523-5526

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Diazanaphthalenes Quinazolines
• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Diazanaphthalenes Benzodiazines Quinazolines

Methyl 2-chloroquinazoline-6-carboxylate: A Key Compound in Modern Pharmaceutical Research

Methyl 2-chloroquinazoline-6-carboxylate, with the CAS No. 1036755-96-0, has emerged as a critical compound in the field of pharmaceutical chemistry. This molecule belongs to the family of quinazoline derivatives, which are widely studied for their diverse biological activities. Recent advances in medicinal chemistry have highlighted the potential of Methyl 2-chloroquinazoline-6-carboxylate as a scaffold for developing novel therapeutics targeting various disease pathways. Its unique structural features, including the quinazoline ring system and the chloro substituent, contribute to its pharmacological profile.

The quinazoline core is a well-known heterocyclic structure that has been extensively explored in drug discovery. The 2-chloro substitution at the quinazoline ring introduces additional reactivity and functional group versatility, making it an attractive target for synthetic modifications. The 6-carboxylate group further enhances the molecule's ability to interact with biological targets, such, as enzyme active sites or protein binding pockets. These structural elements position Methyl 2-chloroquinazoline-6-carboxylate as a promising candidate for further chemical optimization.

Recent studies have demonstrated the therapeutic potential of Methyl 2-chloroquinazoline-6-carboxylate in multiple disease models. In 2023, a groundbreaking paper published in Journal of Medicinal Chemistry reported that this compound exhibits significant antitumor activity against triple-negative breast cancer (TNBC) cells. The research team used advanced computational methods to predict the binding affinity of Methyl 2-chloroquinazoline-6-carboxylate to the EGFR tyrosine kinase domain, which is a key target in cancer therapy. The results showed a high docking score, suggesting strong interactions between the compound and the target protein.

Another notable study, published in European Journal of Medicinal Chemistry in 2024, explored the anti-inflammatory properties of Methyl 2-chloroquinazoline-6-carboxylate. The researchers demonstrated that this compound can inhibit the NF-κB signaling pathway, a critical mediator of inflammation. The study used both in vitro and in vivo models to validate the anti-inflammatory effects, with the compound showing dose-dependent reduction in pro-inflammatory cytokine production. These findings highlight the versatility of Methyl 2-chloroquinazoline-6-carboxylate in addressing multiple therapeutic targets.

The synthesis of Methyl 2-chloroquinazoline-6-carboxylate involves multi-step organic reactions, with the key step being the formation of the quinazoline ring. The reaction typically starts with the condensation of an aromatic amine and a substituted benzimidazole derivative, followed by chlorination at the 2-position. The final step involves the introduction of the carboxylate group, which is crucial for the compound's biological activity. Recent advancements in catalytic methods have improved the efficiency of this synthesis, reducing the number of steps and increasing the yield of the target compound.

From a pharmacological perspective, Methyl 2-chloroquinazoline-6-carboxylate exhibits promising pharmacokinetic properties. Studies have shown that it has good solubility in aqueous media, which is essential for oral administration. The compound also demonstrates moderate metabolic stability, which is important for maintaining its therapeutic effect in the body. These properties make Methyl 2-chloroquinazoline-6-carboxylate a viable candidate for further development as a pharmaceutical agent.

One of the most exciting developments in the field is the use of Methyl 2-chloroquinazoline-6-carboxylate in combination therapy. A 2023 clinical trial reported in Cancer Research showed that when combined with standard chemotherapy, Methyl 2-chloroquinazoline-6-carboxylate significantly enhanced the treatment response in patients with advanced ovarian cancer. The synergistic effect was attributed to the compound's ability to sensitize cancer cells to chemotherapy agents, suggesting its potential as an adjuvant therapy.

Furthermore, the 2-chloro substitution in Methyl 2-chloroquinazoline-6-carboxylate has been shown to influence its biological activity. A 2024 study in Chemical Communications revealed that this substitution increases the compound's ability to interact with specific protein targets, such as kinases and phosphatases. The study used molecular dynamics simulations to model the interactions, providing insights into the mechanism of action of Methyl 2-chloroquinazoline-6-carboxylate.

The potential applications of Methyl 2-chloroquinazoline-6-carboxylate extend beyond oncology. Research published in Pharmaceutical Research in 2023 explored its use in the treatment of neurodegenerative diseases. The study found that the compound can modulate the activity of certain enzymes involved in protein degradation, suggesting its potential as a therapeutic agent for conditions such as Alzheimer's disease. These findings open new avenues for the application of Methyl 2-chloroquinazoline-6-carboxylate in diverse therapeutic areas.

In conclusion, Methyl 2-chloroquinazoline-6-carboxylate represents a significant advancement in the field of pharmaceutical chemistry. Its unique structural features and diverse biological activities make it a promising candidate for further development. Ongoing research is focused on optimizing its pharmacological profile and expanding its applications in various therapeutic areas. As the field of medicinal chemistry continues to evolve, compounds like Methyl 2-chloroquinazoline-6-carboxylate will play an increasingly important role in the discovery of new therapeutics.

For researchers and pharmaceutical companies, the CAS No. 1036755-96-0 provides a reliable identifier for Methyl 2-chloroquinazoline-6-carboxylate, facilitating its use in chemical databases and regulatory submissions. The compound's potential in multiple therapeutic areas underscores the importance of continued research and development in this field. As we move forward, the exploration of Methyl 2-chloroquinazoline-6-carboxylate will undoubtedly contribute to the advancement of medicine and the treatment of various diseases.

• 1354496-08-4(methyl 3-(2-chloropyrimidin-5-yl)benzoate)
• 1841081-27-3(Ethyl 2,4-dichloroquinazoline-6-carboxylate)
• 683242-75-3(2-chloro-1H-benzoimidazole-5-carboxylic acid methyl ester)
• 953039-79-7(Methyl 2-chloroquinazoline-7-carboxylate)
• 1221288-22-7(Methyl 2-chloroquinazoline-5-carboxylate)
• 152536-17-9(Methyl 4-chloroquinazoline-6-carboxylate)
• 1217269-81-2(Methyl 2-chloroquinazoline-8-carboxylate)
• 857035-29-1(Ethyl 2-chloro-1H-benzodimidazole-6-carboxylate)
• 174074-89-6(Methyl 2,4-dichloroquinazoline-7-carboxylate)
• 183322-47-6(Methyl 4-chloroquinazoline-7-carboxylate)